From: Comparing drug safety of hepatitis C therapies using post-market data
FAERS | Cerner Health Facts EHR | ||||
---|---|---|---|---|---|
AE name | OR(CI) before adjustment | OR(CI) after adjustment | AE name | OR(CI) before adjustment | OR(CI) after adjustment |
“Ascites” | 2.04 (1.66, 2.52) | 1.73 (1.40, 2.14) | “Weight decreased” | 3.31(1.88, 5.82) | 2.96(1.68, 5.21) |
“Blood Bilirubin Increased” | 1.98 (1.55, 2.51) | 1.79 (1.41, 2.29) | “Dizziness” | 1.51(0.97, 2.34) | 1.85(1.18, 2.90) |
“Headache” | 1.74 (1.59, 1.90) | 1.87 (1.71, 2.05) | “Dyspnoea” | 1.78(1.41, 2.23) | 2.01(1.59, 2.54) |
“Off Label Use” | 5.58 (2.72, 6.58) | 5.49 (4.64, 6.51) | “Pneumonia” | 2.11(1.75, 2.54) | 2.27(1.88, 2.74) |
“Abdominal Pain” | 1.15 (0.95, 1.42) | 1.23 (1.00, 1.51) | “Diarrhoea” | 1.72(1.37, 2.17) | 1.60(1.27, 2.01) |